Survey finds financial health often suffers, too
by jackie342 on Wed Feb 13, 2013 07:16 PM
I just received this information from another site that I get emails from.( I search day and night for somehting to help my husband. We are in our 6th round of tem. and the last MRI showed re-growth in the tumor bed and 2 other tumors outside the bed.)
TRAIL helps the immune system suppress tumor development. Because protein is part of the immune system, it is not toxic to the body like Chemo. or Rad.
The researcher was from Penn. State University, is an oncologist and his name is Wafik EL-Deiry. This research was done on mice with great success and the article came out on Feb.8th. I know that some of you are great at research, so if you know anything about this, please pass on. I would think this would be easy to trigger in the human body since it is already there. Jackie
by Bee_Rich on Wed Feb 13, 2013 11:31 PM
article title: Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects.
Recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an antitumor protein that is in clinical trials as a potential anticancer therapy but suffers from drug properties that may limit efficacy such as short serum half-life, stability, cost, and biodistribution, particularly with respect to the brain. To overcome such limitations, we identified TRAIL-inducing compound 10 (TIC10), a potent, orally active, and stable small molecule that transcriptionally induces TRAIL in a p53-independent manner and crosses the blood-brain barrier. TIC10 induces a sustained up-regulation of TRAIL in tumors and normal cells that may contribute to the demonstrable antitumor activity of TIC10. TIC10 inactivates kinases Akt and extracellular signal-regulated kinase (ERK), leading to the translocation of Foxo3a into the nucleus, where it binds to the TRAIL promoter to up-regulate gene transcription. TIC10 is an efficacious antitumor therapeutic agent that acts on tumor cells and their microenvironment to enhance the concentrations of the endogenous tumor suppressor TRAIL.
Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.
Ill check my univ library and see if they hold a script to the jornal an download a pdf
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
If you were considering traveling for cancer treatment, which headline would you find more interesting?
Destination: HOPE. Cancer care that is worth the trip.
Over 84% of our patients travel to our hospital from another state
Neither headline is interesting
We care about your feedback. Let us know how we can improve your CancerCompass experience.